{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:33:21Z","timestamp":1786448001389,"version":"build-2736575974"},"reference-count":39,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002132","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:33:39Z","timestamp":1069367619000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes"],"prefix":"10.1002","volume":"2010","author":[{"given":"Kirk","family":"Magee","sequence":"first","affiliation":[{"name":"Dalhousie University; Department of Emergency Medicine; Queen Elizabeth II Health Sciences Centre, Halifax Infirmary 1796 Summer Street Halifax Nova Scotia Canada B3H 3A7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William W","family":"Sevcik","sequence":"additional","affiliation":[{"name":"Capital Health Authority; Division of Emergency Medicine; 1G1.50 WMC 8440-112 Street Edmonton Alberta Canada T6G 2B7"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moher","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute; Box 208, 501 Smyth Road Ottawa Ontario Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H","family":"Rowe","sequence":"additional","affiliation":[{"name":"University of Alberta; Department of Emergency Medicine; Room 1G1.43 Walter C. Mackenzie Health Sciences Centre 8440 112th Street Edmonton Alberta Canada T6G 2B7"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,1,20]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD002132-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease","volume":"337","author":"Cohen","year":"1997","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD002132-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1053\/euhj.1999.1879","article-title":"Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of infractionated heparin in the inital management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAXiparine in Ischaemic Syndrome)","volume":"20","author":"The FRAX.I.S. Study Group","year":"1999","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD002132-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.96.1.61","article-title":"Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo fo 6 weeks in the mangement of unstable coronary artery disease: Fragmin in Unstable Coronary Artery Disease Study (FRIC)","volume":"96","author":"Klein","year":"1997","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002132-BIB0004|cit4","first-page":"259","article-title":"Comparison of low molecular weight heparin and unfractionated heparin in the treatment of unstable angina","volume":"126","author":"Godoy","year":"1998","journal-title":"Rev Med Chile"},{"issue":"2","key":"10.1002\/14651858.CD002132-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0735-1097(95)80001-W","article-title":"Low molecular weight heparin versus tegular heparin or aspirin in the treatment of unstable angina and silent ischemia","volume":"26","author":"Gurfinkel","year":"1995","journal-title":"JACC"},{"key":"10.1002\/14651858.CD002132-BIB0006|cit6","first-page":"159","article-title":"Comparison of clinical outcome of fixed-dose subcutaneous low molecular weight heparin (Tinzaprin) with conventional heparin in unstable angina: a pilot study","volume":"49","author":"Suvarna","year":"1997","journal-title":"Indian Heart Journal"},{"key":"10.1002\/14651858.CD002132-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1161\/01.CIR.100.15.1593","article-title":"Enoxaparin prevents death and cardiac ischemic events in unstable angina\/non-Q-wave myocardial infarction: Results of the Thrombolysis In Myocardial Infarction (TIMI) 11B Trial","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002132-BIB0008|cit8","first-page":"228","article-title":"Advantages of enoxaparin (Clexane(TM)) in comparioson with unfractionated heparin in unstable angina pectoris","volume":"14","author":"Ahrens","year":"1998","journal-title":"Therapiewoche Schweiz"},{"key":"10.1002\/14651858.CD002132-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0002-9149(98)00069-1","article-title":"Heparin is more effective than Inogatran, a low molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease","volume":"81","author":"Adnersen","year":"1998","journal-title":"American Journal of Cardiology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002132-BIB0010|cit10","first-page":"409A","article-title":"Low molecular weight heparin vs regular heparin in the treatment of patients with unstable angina","volume":"February","author":"Bednarkiewicz","year":"1997","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0011|cit11","first-page":"475","article-title":"The role of low molecular weight heparin in unstable anigina, acute myocardial infarction and post-elective percutaneous transluminal coronary angioplasty","volume":"65","author":"Correia","year":"1995","journal-title":"Arq Bras Cardiol"},{"issue":"February","key":"10.1002\/14651858.CD002132-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"326A","DOI":"10.1016\/S0735-1097(96)82207-8","article-title":"Comparison between low molecular weight heparin and standard heparin in unstable angina","volume":"Suppl","author":"Correia","year":"1996","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0013|cit13","first-page":"92","article-title":"Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease","volume":"5","author":"Fox","year":"1998","journal-title":"British Journal of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low molecular weight heparin during instability in coronary artery disease","volume":"347","author":"The FRISC Study Group","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002132-BIB0015|cit15","first-page":"27","article-title":"Use of fragmin (low molecular weight heparin) in patients with unstable angina","volume":"72","author":"Kirichenko","year":"1994","journal-title":"Klinicheskaia Medistina"},{"key":"10.1002\/14651858.CD002132-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1053\/euhj.1998.1054","article-title":"Incidence, outcome and prediction of early clinical event following percutaneous transluminal coronary angioplasty. A compariosn between treatment with reviparin and unfractionated heparin and placebo (results of a substudy of the REDUCE trial)","volume":"19","author":"Preisack","year":"1998","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002132-BIB0017|cit17","first-page":"555","article-title":"Low molecular weight heparins","volume":"93","author":"Talley","year":"1997","journal-title":"Journal of the Arkansas Medical Society"},{"key":"10.1002\/14651858.CD002132-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0735-1097(97)00094-6","article-title":"Dose-ranging trial of enoxaprin for unstable angina: results of TIMI 11A","volume":"29","author":"TIMI 11A Trial Investigators","year":"1997","journal-title":"Journal of the Anerican College of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/oxfordjournals.eurheartj.a015467","article-title":"A low molecular weight, selective thromgin inhibitor, inogatran vs heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study","volume":"18","author":"TRIM Study Group","year":"1997","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD002132-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(01)05775-0","article-title":"Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction","volume":"358","author":"The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators","year":"2001","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002132-BIB0021|cit21","first-page":"I","article-title":"Part 7: The era of reperfusion. Section 1: Acute coronary syndromes (acute myocardial infarction)","volume":"102 (Suppl 1)","author":"ACLS","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002132-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1161\/01.CIR.94.5.911","article-title":"Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial","volume":"94","author":"Antman","year":"1996","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002132-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002132-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1161\/01.CIR.102.10.1193","article-title":"ACC\/AHA guidelines for the management of patients with unstable angina and non ST-segment elevation of myocardial infarction: Executive summary and recommendations: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina)","volume":"102","author":"Braunwald","year":"2000","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD002132-BIB0025|cit25","first-page":"239","article-title":"One year mortality outcomes of all coronary and intensive care unit patients with acute myocardial infarction, unstable angina or other chest pain in Hamilton, Ontario, a city of 375,000 people","volume":"319","author":"Cairns","year":"1989","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0026|cit26","first-page":"11E","article-title":"Approaches to the treatment of unstable angina and non-W wave myocardial infarction","volume":"14 (Suppl E)","author":"Cohen","year":"1998","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1056\/NEJM199709043371001","article-title":"Low molecular weight heparin is an effective and safe treatment for deep-vein thrombosis and pulmonary emoblism","volume":"337","author":"The Columbus Investigators","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002132-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/S0140-6736(00)02324-2","article-title":"Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis","volume":"355","author":"Eikelboom","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002132-BIB0029|cit29","first-page":"28E","article-title":"Low molecular weight heparins: are they different?","volume":"14 (Suppl E)","author":"Fareed","year":"1998","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"24C","DOI":"10.1016\/S0002-9149(99)80467-6","article-title":"Elucidation of the role of plaque instability and rupture in acute coronary events","volume":"76","author":"Fuster","year":"1995","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD002132-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJM199309023291001","article-title":"An international randomized trial compaing four thrombolytic strategies for acute myocardial infarction","volume":"329","author":"The GUSTO Investigators","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002132-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quailty of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Cont Clin Trials"},{"key":"10.1002\/14651858.CD002132-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/archinte.1995.00430060059007","article-title":"Treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis","volume":"155","author":"Lensing","year":"1995","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD002132-BIB0034|cit34","article-title":"Cochrane Collaboration Handbook Section VI","volume-title":"The Cochrane Library","author":"Mulrow","year":"1994"},{"key":"10.1002\/14651858.CD002132-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/0140-6736(90)92336-G","article-title":"Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease","volume":"336","author":"The RISC Group","year":"1990","journal-title":"Lancet"},{"issue":"14","key":"10.1002\/14651858.CD002132-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jama.282.14.1371","article-title":"Users' guides to the medical literature. XIX. Applying clinical trial results B. Guidelines for determining whether a drug is exerting (more than) a class effect","volume":"282","author":"McAlister","year":"1999","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002132-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","article-title":"Low molecular weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis","volume":"100","author":"Siragusa","year":"1996","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD002132-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002132-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199505183322003","article-title":"Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin","volume":"332","author":"Warkentin","year":"1995","journal-title":"New England Journal of Medicine"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002132\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:52:21Z","timestamp":1786445541000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002132"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2003,1,20]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2010,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002132","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,20]]}}}